SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is facing intense market volatility and significant selling pressure after the LUGANO Phase 3 trial failed to meet its primary endpoint in the full dataset. While some investors are debating the potential of post-hoc analysis and focusing on upcoming LUCIA trial results, the community is deeply divided between those viewing the steep decline as an overreaction and others warning of further dilution and long-term risks.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is facing intense downward pressure driven by a legal ruling that denies Section 230 immunity in addiction-related lawsuits, compounded by significant pre-arranged insider stock sales from leadership. While some investors argue that robust user growth and AR technology provide long-term value, the community remains deeply divided between those betting on a recovery and others frustrated by consistent dilution and lackluster price action.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as community sentiment heats up following a major competitor's Phase III trial failure, which investors view as a significant de-risking event for Ocular's lead drug candidate. Discussions are heavily focused on the potential for an accelerated buyout and whether this competitive setback provides the clarity needed for an imminent FDA filing.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing selling pressure as traders react to a BofA report highlighting off-balance-sheet financing risks and concerns over shifting product margins. Despite this volatility, the community remains divided, with bulls viewing the pullback as a buying opportunity given the company's strong AI infrastructure demand while skeptics point to technical weakness and valuation concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as community discourse intensifies around its political association with Donald Trump and ongoing volatility in the Middle East, with investors and social media users debating the potential long-term risks and speculative nature of the stock.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is gaining significant market attention as a leading non-Chinese tungsten producer, further bolstered by the announcement of a large-scale share buyback program that underscores management's confidence in the firm's strategic position. The community is actively discussing the stock's role in rebuilding Western critical-minerals supply chains and is closely monitoring its ramp-up toward full capacity at the Sangdong mine as a major competitive catalyst.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing investor interest as it scales its modular edge data center deployments, driven by an expanding pipeline of high-density AI infrastructure contracts and strategic partnerships. The community remains closely focused on the company's ability to execute on its infrastructure projects and the potential for continued revenue growth within the high-demand edge computing sector.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as bond vigilantes and market participants grapple with the implications of the U.S. and Japan's coordinated currency intervention aimed at stabilizing the yen. Investors are actively debating whether these monetary shifts and persistent geopolitical uncertainties in the Strait of Hormuz will force the Fed to shift its policy stance, leading to heightened volatility across Treasury and equity markets.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as investors debate its valuation disconnect relative to high-flying cybersecurity peers like CrowdStrike and Palo Alto Networks, with many highlighting its lower price-to-sales ratio and potential as an M&A target. Community discussion focuses on its advanced AI security tech, strategic partnerships, and an equity stake in Anthropic that could drive significant long-term value despite recent downward price pressure.

Quantum Corp. engages in the manufacture of computer storage devices. It provides solutions for storing and protecting information in physical, virtual, and cloud environments. Its products and services include Myriad All-Flash File and Object, StorNext File System Unified Surveillance Platform, ActiveScale Object Storage, DXi Backup Appliances, Scalar Tape Storage, CatDV Media Asset Management, and Cloud-Based Analytics. The company was founded by Joel N. Harrison and James M. McCoy in 1980 and is headquartered in Centennial, CO.

Quantum Corp

Quantum Corp (QMCO) is seeing intense volatility as the community remains divided between those betting on an AI-driven storage turnaround and those anticipating a liquidity-fueled 'pump and dump' ahead of a pending share lock-up expiration. Traders are actively debating whether the stock's recent aggressive price action is supported by fundamental demand for data infrastructure or if it is being driven by algorithmic manipulation and artificial short-squeezes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries 

Five stocks stand out as potentially undervalued by price-to-book measures, including BioMarin Pharmaceutical, Invesco and Centene.

5 Undervalued Price-to-Book Stocks Worth Buying in August

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?

The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston PR Newswire SAN RAFAEL, Calif...

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

$BMRN Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.23 down -81.60% YoY
• Reported revenue of $989.71M up 19.91% YoY
• BioMarin Pharmaceutical Inc. raised its full-year 2026 total revenue guidance to a range of $3.875 billion to $3.925 billion, with VOXZOGO revenue expected to reach at least $1 billion in 2026.

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$1.36	--	--	N/A
Q2 '26	$0.95	$1.20	26.98%	BEAT
Q1 '26	$0.69	$0.76	9.59%	BEAT
Q4 '25	$0.17	-$0.24	-241.66%	MISSED
Q3 '25	$0.81	-$0.16	-119.77%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings